Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) shares traded down 3.5% during mid-day trading on Wednesday . The company traded as low as $4.88 and last traded at $4.93, with a volume of 514,071 shares traded. The stock had previously closed at $5.11.

A number of research analysts have recently issued reports on the stock. Chardan Capital restated a “buy” rating and issued a $10.00 price target on shares of Aralez Pharmaceuticals in a research report on Sunday. Guggenheim restated a “buy” rating and issued a $12.00 price target on shares of Aralez Pharmaceuticals in a research report on Monday.

The stock’s 50-day moving average price is $3.78 and its 200-day moving average price is $4.25. The company’s market cap is $322.29 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. The company had revenue of $12.60 million for the quarter, compared to analyst estimates of $9.70 million. The company’s quarterly revenue was up 142.3% compared to the same quarter last year. Analysts expect that Aralez Pharmaceuticals Inc. will post ($0.99) earnings per share for the current fiscal year.

In related news, insider James Patrick Tursi bought 10,000 shares of the stock in a transaction that occurred on Friday, May 20th. The shares were acquired at an average cost of $3.75 per share, with a total value of $37,500.00. Following the completion of the purchase, the insider now directly owns 179,368 shares of the company’s stock, valued at approximately $672,630. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.